BCM
AGRX

Bridgeway Capital Management’s Agile Therapeutics AGRX Stock Holding History

Bridgeway Capital Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-61
Closed -$60K – 1487
2018
Q2 		$60K Sell
61
-36
-37% -$126K ﹤0.01% 1389
2018
Q1 		$499K Buy
97
+35
+56% +$231K 0.01% 1096
2017
Q4 		$335K Hold
62
– – ﹤0.01% 1188
2017
Q3 		$549K Buy
62
+1
+2% +$7.68K 0.01% 1068
2017
Q2 		$458K Sell
61
-38
-38% -$263K 0.01% 1115
2017
Q1 		$631K Buy
99
+41
+71% +$206K 0.01% 980
2016
Q4 		$663K Sell
58
-25
-30% -$350K 0.01% 967
2016
Q3 		$1.15M Buy
83
+27
+48% +$385K 0.02% 739
2016
Q2 		$855K Buy
56
+22
+65% +$301K 0.01% 841
2016
Q1 		$418K Hold
34
– – 0.01% 1116
2015
Q4 		$657K Hold
34
– – 0.01% 948
2015
Q3 		$454K Buy
34
+10
+42% +$178K 0.01% 1081
2015
Q2 		$421K Buy
24
+19
+380% +$405K 0.01% 1148
2015
Q1 		$95K Buy
+5
New +$87.6K ﹤0.01% 1417

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bridgeway Capital Management's AGRX Position: Q3 2018 in Review

Bridgeway Capital Management sold out of Agile Therapeutics (AGRX) in Q3 2018, closing a stake of 61 shares — an estimated $60K sold.

Bridgeway Capital Management first reported a position in AGRX in Q1 2015 and held it in 14 quarters. The position peaked at $1.15M in Q3 2016. 29 funds tracked by Wall St. Rank hold AGRX as of Q3 2018.

  • Bridgeway Capital Management reported no remaining Agile Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Bridgeway Capital Management sold 61 Agile Therapeutics shares in Q3 2018, an estimated $60K.
  • Bridgeway Capital Management first reported a position in Agile Therapeutics in Q1 2015 and held it in 14 quarters.
  • Bridgeway Capital Management's Agile Therapeutics position peaked at $1.15M in Q3 2016.
  • 29 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2018.

Based on Bridgeway Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.